HSIC
Henry Schein, Inc.
NASDAQ · Healthcare · Medical - Distribution · US
$89.94
−1.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 13.6B | 13.2B | 12.7B | 12.3B | 12.6B |
| Cost of Revenue | 9.5B | 9.3B | 8.9B | 8.7B | 9.0B |
| Gross Profit | 4.1B | 3.8B | 3.8B | 3.7B | 3.6B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 3.2B | 3.1B | 3.0B | 2.9B | 2.7B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 149.0M | — | — | — | — |
| Total Operating Expenses | 3.3B | 3.1B | 3.0B | 2.9B | 2.7B |
| Cost and Expenses | 12.8B | 12.4B | 11.9B | 11.6B | 11.7B |
| Operating Income (EBIT) | 774.0M | 758.0M | 729.0M | 714.0M | 938.0M |
| Non-Operating | |||||
| Interest Income | 33.0M | 33.0M | 24.0M | 17.0M | 17.0M |
| Interest Expense | 159.0M | 150.0M | 131.0M | 87.0M | 44.0M |
| Net Interest Income | (126.0M) | (117.0M) | (107.0M) | (70.0M) | (27.0M) |
| Other Non-Op Income/Expense | (216.0M) | (213.0M) | (203.0M) | (158.0M) | (202.0M) |
| Non-Operating Income (excl Interest) | 56.0M | 63.0M | 85.0M | 85.0M | 173.0M |
| EBT (Pre-Tax Income) | 558.0M | 545.0M | 526.0M | 556.0M | 736.0M |
| Income Tax Expense | 132.0M | 126.0M | 128.0M | 120.0M | 170.0M |
| Bottom Line | |||||
| Net Income | 403.0M | 398.0M | 390.0M | 416.0M | 538.0M |
| Earnings from Cont. Ops | 426.0M | 419.0M | 398.0M | 436.0M | 566.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 403.0M | 398.0M | 390.0M | 416.0M | 538.0M |
| Per Share | |||||
| Basic EPS | $3.46 | $3.29 | $3.07 | $3.18 | $3.95 |
| Diluted EPS | $3.43 | $3.27 | $3.05 | $3.16 | $3.91 |
| Revenue Per Share | $119.89 | $109.13 | $99.95 | $94.47 | $92.95 |
| Shares | |||||
| Basic Shares Outstanding | 113.5M | 120.8M | 126.8M | 130.6M | 136.1M |
| Diluted Shares Outstanding | 114.4M | 121.7M | 127.8M | 131.7M | 137.8M |
| Profitability Metrics | |||||
| EBITDA | 1.0B | 1.0B | 941.0M | 877.0M | 977.0M |
| D&A | 313.0M | 311.0M | 297.0M | 248.0M | 212.0M |
| EBIT | 718.0M | 695.0M | 644.0M | 629.0M | 765.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026